Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery

Current Topics in Medicinal Chemistry

Volumn 9, Issue 5, 2009, Pages 452-463

  Marino Jr , Joseph P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

DHETs; Dihydroxyeicosatrienoic acids; EETs; Ephx2; Epoxyeicosatrienoic acids; P450 monooxygenase; Soluble epoxide hydrolase

Indexed keywords

12 (3 ADAMANTYL 1 YLUREIDO)DODECANOIC ACID; AEPO; BENZAMIDE DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENZYME INHIBITOR; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; INTERCELLULAR ADHESION MOLECULE 1; N CYCLOHEXYL N DECYLUREA; PYRIDONE DERIVATIVE; SOLUBLE EPOXIDE HYDROLASE; SOLUBLE EPOXIDE HYDROLASE INHIBITOR; TUPS; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLODYNIA; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CRYSTALLOGRAPHY; DRUG POTENCY; DRUG STRUCTURE; ENDOTHELIUM; FATTY ACID METABOLISM; GENETIC POLYMORPHISM; HEART PROTECTION; HUMAN; HYDROLYSIS; HYPERPOLARIZATION; HYPERTENSION; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DESIGN; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SMALL MOLECULE LIBRARIES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 66649116553     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609788340805     Document Type: Review

References (77)

1. Imig, J. D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardio. Drug Rev. 2006, 24(2), 169-188.
2. Chiamvimonvat, N.; Ho, C.-M.; Tsai, H.-J.; Hammock, B. D. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J. Cardiovasc. Pharmacol. 2007, 50(3), 225-237.
3. Imig, J. D. Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opin. Drug Metab. Toxicol. 2008, 4(2), 165-174.
4. Morisseau, C.; Hammock, B. D. Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 311-333.
5. Newman, J. W.; Morisseau, C.; Harris, T. R.; Hammock, B. D. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. USA 2003, 100, 1558-1563.
6. Gomez, G. A.; Morisseau, C.; Hammock, B. D.; Christianson, D. W. Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 2004, 43, 4716-4723.
7. Lacourciere, G. M.; Armstrong, R. N. The catalytic mechanism of microsomal epoxide hydrolase involves an ester intermediate. J. Am. Chem. Soc. 1993, 115(22), 10466-10467.
8. Borhan, B.; Jones, A. D.; Pinot, F.; Grant, D. F.; Kurth, M. J.; Hammock, B. D. Mechanism of soluble epoxide hydrolase. J. Biol. Chem. 1995, 270(45), 26923-26930.
9. Argiriadi, M. A.; Morisseau, C.; Goodrow, M. H.; Dowdy, D. L.; Hammock, B. D.; Christianson, D. W. Binding of alkylurea inhibitors to epoxide hydrolase implicates active site tyrosines in substrate activation. J. Biol. Chem. 2000, 275(20), 15265-15270.
10. Yamada, T.; Morisseau, C.; Maxwell, J. E.; Argiriadi, M. A.; Christianson, D. W.; Hammock, B. D. Biochemical evidence for the involvement of tyrosine in epoxide activation during the catalytic cycle of epoxide hydrolase. J. Biol. Chem. 2000, 275(30), 23082-23088.
11. Elbekai, R. H.; El-Kadi, A. O. S. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol. Ther. 2006, 112, 564-587.
12. Spector, A. A.; Norris, A. W. Action of epoxyeicosatrienoic acids on cellular function. Am. J. Pysiol. Cell Physiol. 2007, 292, C996-C1012.
13. Bauersachs, J.; Hecker, M.; Busse, R. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br. J. Pharmacol. 1994, 113, 1548-1553.
14. Campbell, W. B.; Gebremedhin, D.; Pratt, P. F.; Harder, D. R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarization factors. Circ. Res. 1996, 78, 415-423.
15. Fisslthaler, B.; Popp, R.; Kiss, L.; Potente, M.; Harder, D. R.; Fleming, I.; Busse, R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999, 401, 493-497.
16. Imig, J. D.; Navar, L. G.; Roman, R. J.; Reddy, K. K.; Falck, J. R. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol. 1996, 7, 2364-2370.
17. Ye, D.; Zhou, W.; Lu, T.; Jagadeesh, S. G.; Falck, J. R.; Lee, H. C. Mechanism of rat mesenteric K(ATP) activation by 14,15-epoxyeicosatrienoic acid. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(4), H1326-H1336.
18. Larsen, B. T.; Miura, H.; Hatoum, O. A.; Campbell, W. B.; Hammock, B. D.; Zeldin, D. C.; Falck, J. R.; Gutterman, D. D. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: Implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H491-H499.
19. Fleming, I.; Busse, R. Endothelium-derived epoxyeicosatrienoic acids and vascular function. Hypertension 2006, 47, 629-633
20. Imig J. D.; Zhao Xueying; Zaharis C. Z.; Olearczyk J.J.; Pollock D. M.; Newman J. W.; Kim I. H.; Watanabe T.; Hammock B. D. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005, 46(4), 975-81.
21. Loch, D.; H., Andrew; Morisseau, C.; Hammock, B. D.; Brown, L. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem. Biophys. 2007, 47(1), 87-97.
22. Ghosh, S.; Chiang P.; Wahlstrom J. L.; Fujiwara H.; Selbo, J. G.; Roberds, S. L. Oral delivery of 1,3-dicyclohexylurea nanosus-pension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin. Pharmacol. Toxicol. 2008, 102(5), 453-458.
23. Li, J.; Carroll, M. A.; Chander, P. N.; Falek, J. R.; Sangras, B.; Stier, C. T. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. Frontiers in Bioscience 2008, 13 3480-3487.
24. Sinal, C. J.; Miyata, M.; Tohkin, M.; Nagata, K.; Bend, J. R.; Gonzalez. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J. Biol. Chem. 2000, 275(51), 40504-40510.
25. Luria, A.; Weldon, S. M.; Kabcenell, A. K.; Ingraham, R. H.; Matera, D.; Jiang, H.; Gill, R.; Morisseau, C.; Newman, J. W.; Hammock, B. D. Compensatory mechanism for homeostatic blood pressure regulation in EPHX2 gene-disrupted mice. J. Biol. Chem. 2007, 282(5), 2891-2898.
26. Zhu, D.; Bousamra, M.; Zeldin, D. C.; Falck, J. R.; Townsley, M.; Harder, D. R.; Roman, R. J.; Jacobs, E. R. Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries. Am. J.Physiol. Lung Cell Mol. Physiol. 2000, 278, L335-L343.
27. Keserü, B.; Barbosa-Sicard, E.; Popp, R.; Fisslthaler, B.; Dietrich, A.; Gudermann, T.; Hammock, B. D.; Falck, J. R.; Weissmann, N.; Busse, R.; Fleming, I. Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and acute hypoxic pulmonary vasoconstrictor response. FASEB 2008, 22, 1-10.
28. Node, K.; Huo, Y.; Ruan, Z.-X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D. C.; Liao, J. K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999, 285(5431), 1276-1279.
29. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T.-S.; Fang, X.; Zhu, Y.; Spector, A. A.; Gill, S.; Morisseau, C.; Hammock, B. D.; Shyy, J. X.-J. The anti-inflammatory effect of laminar flow: The role of PPARγ, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA 2005, 102(46), 16747-16752.
30. Inceoglu, B.; Jinks, S. L.; Schmelzer, K. R.; Waite, T.; Kim, I. H.; Hammock, B. D. Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. Life Sci. 2006, 79(24), 2311-2319.
31. Fife, K. L.; Liu, Y.; Schmelzer, K. R.; Tsai, H.-J.; Kim, I.-H.; Morisseau, C.; Hammock, B. D.; Kroetz, D. L. Inhibition of Soluble Epoxide Hydrolase Does Not Protect against Endotoxin-Mediated Hepatic Inflammation. J. Pharmacol. Exp. Ther. 2008, 327(3), 707-715.
32. Webb, H.; Kay, H. Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis and other autoimmune induced inflammation disorders. WO08058033A2, 2008.
33. Larsen, B. T.; Campbell, W. B.; Gutterman, D. D. Beyond vasodilation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system. TRENDS Pharmacol. Sci. 2008, 28(1), 32-38.
34. Ulu, A.; Davis, B. B.; Tsai, H.-J.; Kim, I.-H.; Morisseau, C.; Inceoglu, B.; Fiehn, O.; Hammock, B. D.; Weiss, R. H. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein E-knockout mouse Model. J. Cardiovasc. Pharmacol. 2008, 52(4), 314-323.
35. Zhao, X.; Yamamoto, T.; Newman, J. W.; Kim, I.-H.; Watanabe, T.; Hammock, B. D.; Stewart, J.; Pollock, J. S.; Pollock, D. M.; Imig, J. D. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J. Am. Soc. Nephrol. 2004, 15(5), 1244-1253.
36. Huang, H.; Morisseau, C.; Wang, J. F.; Yang, T.; Falck, J. R.; Hammock, B. D.; Wang, M.-H. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. 2007, 293(1), F342-F349.
37. Nithipatikom, K.; Moore, J. M.; Isbell, M. A.; Falck, J. R.; Gross, G. J. Epoxyeicosatrienoic acids in cardioprotection: Ischemic vs. reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H537-H542.
38. Xu, D.; Li, N.; He, Y.; Timofeyev, V.; Lu, L.; Tsai, H.-J.; Kim, I.-H.; Tuteja, D.; Mateo, R. K. P.; Singapuri, A.; Davis, B. B.; Low, R.; Hammock, B. D.; Chiamvimonvat, N. Prevention and reversal of cardiac hypertrophy by soluble epoxide inhibitors. Proc. Natl. Acad. Sci. USA 2006, 103(49), 18733-18738.
39. Ai, D.; Pang, W.; Li, N.; Xu, M.; Jones, P. D.; Yang, J.; Zhang, Y.; Chiamvimonvat, N.; Shyy, J. Y.-J.; Hammock, B. D.; Zhu, Y. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 2009, 106(2), 564-569.
40. Monti, J.; Fischer, J.; Paskas, S.; Heinig, M.; Schulz, H.; Gösele, C.; Heuser, A.; Fischer, R.; Schmidt, C.; Schirdewan, A.; Gross, V.; Hummel, O.; Maatz, H.; Patone, G.; Saar, K.; Vingron, M.; Weldon, S. M.; Lindpaintner, K.; Hammock, B. D.; Rohde, K.; Dietz, R.; Cook, S. A.; Schunck, W.-H.; Luft, F. C.; Hubner, N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat. Genet. 2008, 40(5), 529-537.
41. Fornage, M.; Boerwinkle, E.; Doris, P. A.; Jacobs, D.; Liu, K.; Wong, N. D. Polymorphism of the Soluble Epoxide Hydrolase is Associated with Coronary Artery Calicification in African-American Subjects - The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Circulation 2004, 109, 335-339.
42. Lee, C. R.; North, K. E.; Bray, M. S.; Fornage, M.; Seubert, J. M.; Newman, J. W.; Hammock, B. D.; Couper, D. J.; Heiss, G.; Zeldin, D. C. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 2006, 15(10), 1640-1649.
43. Sato, K.; Emi, M.; Ezura, Y.; Fujita, Y.; Takada, D.; Ishigami, T.; Umemura, S.; Xin, Y.; Wu, L. L.; Larrinaga-Shum, S.; Stephenson, S. H.; Hunt, S. C., Hopkins, P. N. Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: Intrafamilial association study in an eight-generation hyperlipidemic kindred. J. Hum. Genet. 2004, 49, 29-34.
44. Enayetallah, A.; Cao, L.; Grant, D. F. Novel role of soluble epoxide hydrolase in regulating cholesterol in mammalian cells. Open Drug Metabol. J. 2007, 1, 1-6.
45. Fang, X.; Hu, S.; Xu, B.; Snyder, G. D.; Harmon, S.; Yao, J.; Liu, Y.; Sangras, B.; Falck, J. R.; Weintraub, N. L.; Spector, A. A. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferators - activated receptor - α. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H55-H63.
46. Ng, V. Y.; Huang, Y.; Reddy, L. M.; Falck, J. R.; Lin, E. T.; Kroetz, D. L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor α. Drug Metab. Dispos. 2007, 35(7), 1126-1134.
47. Ohtoshi, K.; Kaneto, H.; Node, K.; Nakamura, Y.; Shiraiwa, T.; Matsuhisa, M.; Yamasaki, Y. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 2005 331(1), 347-350.
48. Webb, H.; Kay, H. Ureas as soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders and their preparation. WO08094869A1, 2008.
49. Mullin, C. A.; Hammock, B. D.; Chalcone oxides - potent selective inhibitors of cytosolic epoxide hydrolase. Arch. Biochem. Biophys. 1982, 216(2), 423-439.
50. Morisseau, C.; Du, G.; Newman, J. W.; Hammock, B. D. Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. Arch. Biochem. Biophys. 1998, 356(2), 214-228.
51. Morisseau, C.; Goodrow, M. H.; Dowdy, D.; Zheng, J.; Greene, J. F.; Sanborn, J. R.; Hammock, B. D. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. USA 1999, 96, 8849-8854.
52. Yu, Z.; Xu, F.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 2000, 87(11), 992-998.
53. Jung, O.; Brandes, R. P.; In-Hae, K.; Schweda, F.; Schmidt, R.; Hammock, B. D.; Busse, R.; Fleming, I. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005, 45(4), 759-765.
54. Gross, G. J.; Gauthier, K. M.; Moore, J.; Falck, J. R.; Hammock, B. D.; Campbell, W. B.; Nithipatikom, K. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am. J. Physiol. 2008, 294(6), H2838-H2844.
55. Dorrance, A. M.; Rupp, N.; Pollock, D. M.; Newman, J. W.; Hammock, D.; Imig, J. D. An epoxide hydrolase inhibitor, 12-(3- adamantyl-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J. Cardio. Pharm. 2005, 46(6), 842-848.
56. Zhang, W.; Koerner, I. P.; Noppens, R.; Grafe, M.; Tsai, H.-J.; Morisseau, C.; Luria, A.; Hammock, B. D.; Falck, J. R.; Alkayed, N. J. Soluble epoxide hydrolase: A novel therapeutic target in stroke. J. Cereb. Blood Flow Metabol. 2007, 27(12), 1931-1940.
57. Jones, P. D.; Tsai, H.-J.; Do, Z. N.; Morisseau, C.; Hammock, B. D. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 2006, 16, 5212-5216.
58. Kim, I.-H.; Tsai, H.-J.; Nishi, K.; Kasagami, T.; Morisseau, C.; Hammock, B. D. 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic properties. J. Med. Chem. 2007, 50(21), 5217-5226.
59. Hwang, S. H.; Tsai, H.-J.; Liu, J.-Y.; Morisseau, C.; Hammock, B. D. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 2007, 50, 3825-3840.
60. Gless, R. D., Jr. Preparation of phenyl urea and thiourea derivatives as soluble epoxide hydrolase inhibitors. WO08016884A2, 2008.
61. Gless, R. D., Jr. Preparation of benzenesulfonamides as soluble epoxide hydrolase inhibitors for treating cardiovascular, inflammatory, pulmonary, and diabetes-related diseases. WO08040000A2, 2008.
62. Gless, R. D., Jr.; Anandan, S. K.; Aavula, B. R. Phenylurea derivatives as soluble epoxide hydrolase inhibitors. WO08051873A2, 2008.
63. Gless, R. D., Jr.; Anandan, S. K. Preparation of (piperidinyl)adamantanylurea derivatives for use as soluble epoxide hydrolase inhibitors. WO08051875A1, 2008.
64. Hammock, B. D.; Jones, P. D.; Morriseau, C.; Huang, H.; Tsai, H.-J.; Gless, R. D., Jr. Piperidinyl, indolyl, piridinyl, morpholinyl, and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases. WO2007106525A1.
65. Ingraham, R. H. Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders. WO07106706A1, 2007.
66. Delombaert, S.; Eldrup, A. B.; Kowalski, J. A.; Mugge, I. A.; Soleymanzadeh, F.; Swinamer, A. D.; Taylor, S. J. Preparation of piperidinecarboxylic acid benzylamides as soluble epoxide hydrolase inhibitors. WO07106705A1, 2007.
67. Ingraham, R. H.; Proudfoot, J. R. Preparation of arylpyrazoles as soluble epoxide hydrolase inhibitors for the treatment of cardiovascular disease. WO03002555A1, 2003.
68. Fleck, R. W.; Guo, X.; Lo, H. Y.; Man, C. C. Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors and their preparation and pharmaceutical compositions. WO07067836A2, 2007.
69. Cywin, C. L.; De Lombaert, S.; Eldrup, A. B.; Ingraham, R. H.; Taylor, S.; Soleymanzadeh, F. Methods of using inhibitors of soluble epoxide hydrolase against hypertension and other disorders. WO06121719A2, 2006.
70. Taylor, S. J.; Delombaert, S.; Eldrup, A.; Farrow, N.; Mugge, I.; Soleymanzadeh, F. Benzamide inhibitors of soluble epoxide hydrolase. 234th ACS National Meeting, 2007, MEDI-196.
71. Eldrup, A. B.; Soleymanzadeh, F.; Taylor, S. J. N-substituted pyridones or pyrimidones, processes for preparing them, pharmaceutical compositions containing them, and their use as soluble epoxide hydrolase (sEH) inhibitors. WO07044491A1, 2007.
72. Eldrup, A. B.; Farrow, N. A.; Kowalski, J. A.; Delombaert, S.; Mugge, I. A.; Soleymanzadeh, F.; Swinamer, A. D.; Taylor, S. J. Substituted pyridinamide compounds useful as soluble epoxide hydrolase inhibitors. WO07098352A2, 2007.
73. Ota, T.; Takahashi, H.; Kakinuma, H.; Busujima, T. Benzimidazole-5-carboxamide derivatives as soluble epoxide hydrolase inhibitors. WO07043653A1, 2007.
74. Ota, T.; Hirano, H.; Kakinuma, H.; Shimaoka, T.; Kanno, H. Anilide compounds as soluble epoxide hydrolase inhibitors and pharmaceuticals containing them. JP2007126454A, 2007.
75. Xie, Y.; Liu, Y.; Gong, G.; Smith, D. H.; Yan, F.; Rinderspacher, A.; Yan, F.; Rinderspacher, A.; Feng, Y.; Zhu, Z.; Deng, S.-X.; Branden, L.; Vidoviç, D.; Chung, C.; Schürer, S.; Morisseau, C.; Hammock, B. D.; Landry, D. W. Discovery of potent non-urea inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 2009, manuscript in press.
76. Ding, Y.; Marino, J. P.; Li, P.; Londregan, A. T. Novel soluble epoxide hydrolase inhibitors and their use. WO08105968A1, 2008.
77. Patel, D. V.; Gless, R. D., Jr.; Webb, H.; Kay, H.; Anandan, S. K.; Aavula, B. R. Preparation of α-hydroxyamide derivatives and analogs as soluble epoxide hydrolase inhibitors. WO08073623A2, 2008.